Safety and Effectiveness Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Hyperopia

Inclusion Criteria: * Naturally occurring hyperopia up to +6.0 D, with or without astigmatism of +0.50 D to +3.50 D at the spectacle plane, and MRSE ≤ +6.50 D; * Have ≤ 0.75 D of latent hyperopia as determined by the difference between the preoperative MRSE and CRSE; * A stable refraction for at least the last 12 months as documented by previous clinical records, i.e., the spherical and cylindrical portions of the manifest refraction have not progressed at a rate of more than 0.50 D during the year prior to the baseline examination in the eye to be treated; * Hard contact lens wearers must have two central keratometry readings and two manifest refractions taken at least one week apart that do not differ by more than 0.50 D; * Visual acuity correctable to at least 20/40 in both eyes; * Operative eye must be targeted for emmetropia; * At least 21 years of age; * Willing and able to return for scheduled follow up examinations for 24 months after surgery; * Sign and be given a copy of the written Informed Consent form. Exclusion Criteria: * A history of anterior segment pathology, including cataracts (in the operative eye); * Severe dry eye syndrome unresolved by treatment; * Residual, recurrent, active ocular or uncontrolled eyelid disease, corneal scars within the ablation zone or other corneal abnormality such as recurrent corneal erosion or severe basement membrane disease; * Ophthalmoscopic signs of keratoconus (or keratoconus suspect); * An ablation deeper than 250 microns from the corneal endothelium; * Irregular or unstable (distorted/not clear) corneal mires on central keratometry readings; * Blind in the fellow eye; * Undergone previous intraocular or corneal surgery of any kind in the operative eye(s), including any type of excimer laser surgery for either refractive or therapeutic purposes; * A history of ocular Herpes zoster or Herpes simplex keratitis; * A history of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative IOP \>21 mm Hg; * Diabetes, diagnosed autoimmune disease, connective tissue disease, or clinically significant atopic syndrome; * Immunocompromised or use chronic systemic corticosteroid or other immunosuppressive therapy; * Pregnant, lactating, or be of childbearing potential and not practicing a medically approved method of birth control; * A known sensitivity to planned study medications; * Participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation; * At risk for angle closure or for developing strabismus postoperatively. * For Fellow (Second) Eyes in Simultaneous Bilateral Treatment Procedures * 1\. Flap complications during the first eye's surgery such as a free cap, partial flap, thin flap, or irregular flap. * 2\. Epithelial defect exceeding 2 mm x 2 mm in dimension, or clinically significant debris in the interface between the flap and underlying stroma for the first eye. * 3\. Severe blepharospasm in the first eye that may have prevented or impeded the completion of the keratectomy and/or the laser ablation procedure. * 4\. Poor subject cooperation with instructions for the first eye's surgery and/or poor subject fixation on the laser fixation target. * 5\. Aborted LASIK procedure in the first eye or PRK was performed in the first eye because LASIK was not possible.